ArticleBMC ophthalmology2025
Treatment-induced changes in retinal thickness and ocular biometry in hyperopic anisometropic amblyopia: a prospective longitudinal study.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Changes in peripapillary retinal nerve fiber layer thickness, macular fovea thickness, and perimacular retinal nerve fiber layer thickness in children with hyperopic amblyopia.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate treatment-induced changes in retinal structural parameters and ocular biometric measurements in children with hyperopic anisometropic amblyopia following therapy.
methodsThis prospective longitudinal study included 30 children aged 5-7 years with newly diagnosed hyperopic anisometropic amblyopia (21 mild and 9 moderate) and 30 age-matched normal controls. All participants underwent comprehensive ocular examinations, including uncorrected and best-corrected distance visual acuity (BCVA), cycloplegic refraction, and axial length (AL) measurement using the ZEISS IOL Master 700. Additionally, subfoveal retinal thickness, retinal nerve fiber layer (RNFL) thickness, and macular parameters were assessed using spectral-domain optical coherence tomography. Following baseline examinations, patients received refractive correction for 2 months and were subsequently followed for 4 months after occlusion therapy. Ocular biometric and retinal structural parameters were compared before and after amblyopia treatment in amblyopic eyes, fellow eyes, and the right eyes of healthy children.
resultsSignificant improvements in BCVA were observed in amblyopic eyes, improving from 0.21 ± 0.15 logMAR at baseline to 0.11 ± 0.16 logMAR after treatment (p < 0.001). Subfoveal retinal thickness decreased significantly only in amblyopic eyes, from 216.20 ± 19.36 μm to 210.76 ± 15.01 μm (p < 0.001), with no significant changes in fellow eyes (p = 0.097) or normal eyes (p = 0.099). Retinal nerve fiber layer (RNFL) thickness changes were significant only in fellow eyes, showing a reduction from 102.57 ± 9.31 μm to 101.10 ± 9.98 μm (p = 0.008), while amblyopic and normal eyes showed no significant changes (p > 0.05). Axial length (AL) increased significantly in all groups, but the increase in the fellow eyes (22.17±0.90 mm to 22.33 ± 0.89 mm, p < 0.001) was greater than that observed in amblyopic eyes (21.71±0.80 mm to 21.82 ± 0.86 mm, p < 0.001) or normal eyes (22.40±0.57 mm to 22.46 ± 0.59 mm, p < 0.001). Macular parameters and anterior chamber depth remained stable across all groups(p > 0.05).
conclusionsStructural retinal changes were observed in amblyopic eyes and in fellow eyes after patching, with no significant changes in normal eyes. Patching therapy may also lead to greater AL growth in the fellow eye compared to amblyopic or normal eyes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.